MA31913B1 - Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations - Google Patents
Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisationsInfo
- Publication number
- MA31913B1 MA31913B1 MA32913A MA32913A MA31913B1 MA 31913 B1 MA31913 B1 MA 31913B1 MA 32913 A MA32913 A MA 32913A MA 32913 A MA32913 A MA 32913A MA 31913 B1 MA31913 B1 MA 31913B1
- Authority
- MA
- Morocco
- Prior art keywords
- hyaluronic acid
- compositions containing
- drug compositions
- bradykinin
- containing bradykinin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 title abstract 2
- 229920002674 hyaluronan Polymers 0.000 title abstract 2
- 229960003160 hyaluronic acid Drugs 0.000 title abstract 2
- 101800004538 Bradykinin Proteins 0.000 title 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 title 1
- 102100035792 Kininogen-1 Human genes 0.000 title 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
L'invention porte sur des compositions pharmaceutiques contenant, en tant qu'ingrédients actifs, un mélange d'un polymère d'acide hyaluronique avec un antagoniste des récepteurs de la bradykinine B2. Lesdites compositions se sont révélées être particulièrement efficaces dans le traitement de maladies dégénératives des articulations, telles que l'ostéoarthrite, à l'aide d'injections intra-articulaires.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002225A ITMI20072225A1 (it) | 2007-11-23 | 2007-11-23 | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
| PCT/EP2008/009451 WO2009065507A2 (fr) | 2007-11-23 | 2008-11-10 | Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31913B1 true MA31913B1 (fr) | 2010-12-01 |
Family
ID=40314753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32913A MA31913B1 (fr) | 2007-11-23 | 2010-06-15 | Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9101627B2 (fr) |
| EP (1) | EP2222275B1 (fr) |
| JP (1) | JP5383695B2 (fr) |
| KR (1) | KR101585868B1 (fr) |
| CN (1) | CN101868225B (fr) |
| AP (1) | AP2628A (fr) |
| AR (1) | AR069407A1 (fr) |
| AT (1) | ATE529096T1 (fr) |
| AU (1) | AU2008328311B2 (fr) |
| BR (1) | BRPI0820402A2 (fr) |
| CA (1) | CA2706398C (fr) |
| CL (1) | CL2008003475A1 (fr) |
| CO (1) | CO6270301A2 (fr) |
| CR (1) | CR11457A (fr) |
| CY (1) | CY1112134T1 (fr) |
| DK (1) | DK2222275T3 (fr) |
| EA (1) | EA017626B1 (fr) |
| EC (1) | ECSP10010153A (fr) |
| ES (1) | ES2374861T3 (fr) |
| GE (1) | GEP20125602B (fr) |
| HN (1) | HN2010001037A (fr) |
| HR (1) | HRP20110904T1 (fr) |
| IL (1) | IL205860A (fr) |
| IT (1) | ITMI20072225A1 (fr) |
| MA (1) | MA31913B1 (fr) |
| MX (1) | MX2010005484A (fr) |
| MY (1) | MY148685A (fr) |
| NI (1) | NI201000087A (fr) |
| NZ (1) | NZ585514A (fr) |
| PA (1) | PA8804801A1 (fr) |
| PE (1) | PE20091422A1 (fr) |
| PL (1) | PL2222275T3 (fr) |
| PT (1) | PT2222275E (fr) |
| RS (1) | RS52045B (fr) |
| SI (1) | SI2222275T1 (fr) |
| TN (1) | TN2010000215A1 (fr) |
| TW (1) | TWI448292B (fr) |
| UA (1) | UA97867C2 (fr) |
| WO (1) | WO2009065507A2 (fr) |
| ZA (1) | ZA201003586B (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL420378A1 (pl) * | 2014-05-30 | 2017-10-23 | Nataliia Mykolaivna Derkach | Stabilizowany roztwór na bazie substancji czynnych, sposób otrzymywania stabilizowanego roztworu substancji czynnych, kompozycja farmaceutyczna na bazie stabilizowanego roztworu substancji czynnych (dwa warianty) |
| US20170348347A1 (en) * | 2014-12-26 | 2017-12-07 | Seikagaku Corporation | Agent for improving ocular subjective symptoms and method thereof |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| US12221638B2 (en) | 2020-08-07 | 2025-02-11 | Alteogen Inc. | Method for producing recombinant hyaluronidase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
| ITMI20021247A1 (it) * | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
-
2007
- 2007-11-23 IT IT002225A patent/ITMI20072225A1/it unknown
-
2008
- 2008-11-07 TW TW097142981A patent/TWI448292B/zh not_active IP Right Cessation
- 2008-11-10 RS RS20110524A patent/RS52045B/sr unknown
- 2008-11-10 HR HR20110904T patent/HRP20110904T1/hr unknown
- 2008-11-10 EP EP08853047A patent/EP2222275B1/fr active Active
- 2008-11-10 EA EA201000678A patent/EA017626B1/ru not_active IP Right Cessation
- 2008-11-10 MX MX2010005484A patent/MX2010005484A/es active IP Right Grant
- 2008-11-10 AU AU2008328311A patent/AU2008328311B2/en not_active Ceased
- 2008-11-10 WO PCT/EP2008/009451 patent/WO2009065507A2/fr not_active Ceased
- 2008-11-10 AT AT08853047T patent/ATE529096T1/de active
- 2008-11-10 PL PL08853047T patent/PL2222275T3/pl unknown
- 2008-11-10 NZ NZ585514A patent/NZ585514A/en not_active IP Right Cessation
- 2008-11-10 BR BRPI0820402-0A patent/BRPI0820402A2/pt not_active IP Right Cessation
- 2008-11-10 GE GEAP200811807A patent/GEP20125602B/en unknown
- 2008-11-10 JP JP2010534395A patent/JP5383695B2/ja not_active Expired - Fee Related
- 2008-11-10 SI SI200830475T patent/SI2222275T1/sl unknown
- 2008-11-10 KR KR1020107011164A patent/KR101585868B1/ko not_active Expired - Fee Related
- 2008-11-10 DK DK08853047.2T patent/DK2222275T3/da active
- 2008-11-10 US US12/743,891 patent/US9101627B2/en not_active Expired - Fee Related
- 2008-11-10 CN CN2008801169202A patent/CN101868225B/zh not_active Expired - Fee Related
- 2008-11-10 PT PT08853047T patent/PT2222275E/pt unknown
- 2008-11-10 MY MYPI2010002358A patent/MY148685A/en unknown
- 2008-11-10 ES ES08853047T patent/ES2374861T3/es active Active
- 2008-11-10 CA CA2706398A patent/CA2706398C/fr not_active Expired - Fee Related
- 2008-11-10 AP AP2010005265A patent/AP2628A/xx active
- 2008-11-10 UA UAA201006127A patent/UA97867C2/ru unknown
- 2008-11-19 PE PE2008001955A patent/PE20091422A1/es not_active Application Discontinuation
- 2008-11-21 AR ARP080105077A patent/AR069407A1/es unknown
- 2008-11-21 PA PA20088804801A patent/PA8804801A1/es unknown
- 2008-11-21 CL CL2008003475A patent/CL2008003475A1/es unknown
-
2010
- 2010-05-05 EC EC2010010153A patent/ECSP10010153A/es unknown
- 2010-05-06 CO CO10054082A patent/CO6270301A2/es active IP Right Grant
- 2010-05-14 TN TN2010000215A patent/TN2010000215A1/fr unknown
- 2010-05-19 NI NI201000087A patent/NI201000087A/es unknown
- 2010-05-20 HN HN2010001037A patent/HN2010001037A/es unknown
- 2010-05-20 IL IL205860A patent/IL205860A/en not_active IP Right Cessation
- 2010-05-20 ZA ZA2010/03586A patent/ZA201003586B/en unknown
- 2010-05-21 CR CR11457A patent/CR11457A/es unknown
- 2010-06-15 MA MA32913A patent/MA31913B1/fr unknown
-
2011
- 2011-11-30 CY CY20111101177T patent/CY1112134T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA31913B1 (fr) | Compositions pharmaceutiques contenant des antagonistes de la bradykinine et de l'acide hyaluronique, et leurs utilisations | |
| MA33295B1 (fr) | Nouvelle formulation de diclofénac | |
| BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
| MA34765B1 (fr) | Antagonistes des récepteurs de l'acide lysophosphatidique et utilisations de ceux-ci | |
| MA33297B1 (fr) | Production de nanoparticules encapsulées à des fractions volumiques élevées | |
| MA44206A (fr) | Comprimé orodispersible comprenant estetrol | |
| EP1624874A4 (fr) | Derives d'acide 3-amino-4-phenylbutanoique en tant qu'inhibiteurs de dipeptidyl peptidase dans le cadre du traitement ou de la prevention du diabete | |
| MA31283B1 (fr) | Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MA35567B1 (fr) | Nouvelle formulation de méloxicam | |
| TW200744677A (en) | Compositions and methods for preparation of poorly water soluble drugs with increased stability | |
| MA35136B1 (fr) | Formulation pour un anticorps anti-a4b7 | |
| MA31457B1 (fr) | N-(2-(hetaryl)aryl)arylsulfonamides et n-(2-(hetaryl)hetaryl)arylsulfonamides | |
| MA45972B1 (fr) | Unité posologique orodispersible contenant un composant d'estétrol | |
| MA34296B1 (fr) | Composition retard injectable antipsychotique | |
| AR060784A1 (es) | Mezclas binarias de acido hialuronico y su uso terapeutico | |
| EA200802020A1 (ru) | Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1 | |
| ATE521343T1 (de) | Im mund zerfallende zusammensetzungen von rasagilin | |
| EP2142549A4 (fr) | Dérivés d'adénosine, procédé pour la synthèse de ces derniers, et compositions pharmaceutiques pour la prévention et le traitement de maladies inflammatoires contenant lesdits dérivés en tant qu'ingrédients actifs | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| ECSP088408A (es) | Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico | |
| MA32635B1 (fr) | Produit medicamenteux et traitement associe | |
| MA33602B1 (fr) | Composition pharmaceutique permettant de prévenir ou de traiter l'arthrite rhumatoïde, contenant du rébamipide | |
| WO2009019307A3 (fr) | Compositions à base de calcitonine orale et leurs applications | |
| MA38016A1 (fr) | Composition injectable stable contenant du diclofénac et du thiocolchicoside |